Kenneth Maiese
National Heart, Lung, and Blood Institute, United States
- Orcid: 0000-0002-5049-9116
- Publications: N/A
- Citations: N/A
- Keywords: autophagy, apoptosis, neuroscience, oncology, metabolism, trophic factors
Short Bio
- Kenneth Maiese is an internationally recognized physician-scientist, healthcare executive, and editor with broad research, clinical, and leadership experience in academia, the federal government, and industry. He was born and raised in New Jersey and was the Valedictorian of his high school class at Pennsauken High School. He graduated from the University of Pennsylvania Suma cum Laude with Distinction and was a Teagle Scholar, Grupe Scholar, and Joseph Collins Scholar at Weill Medical College of Cornell University. Dr. Maiese subsequently trained as a physician-scientist at Cornell, the National Institutes of Health, and as a senior executive at the Harvard T.H. Chan School of Public Health. He has extensive experience in academic medicine, healthcare delivery, business development, managed care, biotechnology, and drug development holding positions as member and advisor for the National Institutes of Health Biotechnology and Venture Capital Development, National Institutes of Health Innovation Network, Chief Medical Officer, tenured Professor and Chair and Chief of Service of the Department of Neurology and Neurosciences of Rutgers University, Global Head of Translational Medicine and External Innovation, Board Member of the Cancer Institute of New Jersey, Steering Committee Member for the Foundation for the National Institutes of Health, tenured Professor in Neurology, Anatomy & Cell Biology, Molecular Medicine, the Barbara Ann Karmanos Cancer Institute, and the National Institute of Health Center at Wayne State University, and Founding Editor and Editor-in-Chief of multiple highly successful international journals. Dr. Maiese maintains therapeutic and scientific expertise in multiple medical disciplines, regulatory policy, and drug commercialization. His work has elucidated a number of new avenues for the fruitful discovery of innovative strategies to treat neurodegenerative disease, cardiovascular disorders, metabolic dysfunction, and cancer and he has led the development of first-in-class pharmaceuticals. Early in his career, Dr. Maiese has received outstanding investigator awards, has received the Hoechst Award for exceptional basic science work, was named a Johnson & Johnson Distinguished Investigator, was chosen as a Henrietta B. and Frederick H. Bugher Foundation Investigator, has received the Albrecht Fleckenstein Memorial Award for Distinguished Achievement in Basic Research, was elected to America's Top Physicians and The Best of U.S. Physicians, was recipient of Albert Nelson Marquis Lifetime Achievement Award, was elected as an America’s Health Insurance Plans (AHIP) Executive Leadership Fellow, and his highly cited work has received the distinction of "High Impact Research and Potential Public Health Benefit" by the National Institutes of Health. He has been fortunate to have benefited from continuous funding from sources that include the American Diabetes Association, the American Heart Association, the Bugher Foundation, Johnson and Johnson Focused Giving Award, and the National Institutes of Health. His service on Executive Councils for Graduate Schools has fostered innovative graduate student training programs and he was elected as board and advisor member to develop and execute inaugural MD/PhD Degree Programs and new Translational Medicine Programs. He chairs national grant committees, formulates regulatory and utilization management policies for national clinical care guidelines, and is a chartered panel member or consultant for numerous national and international foundations as well as multiple study sections and special emphasis panels for the National Institutes of Health. Dr. Maiese is frequently honored as the chairperson and/or the plenary and keynote speaker for a number of international symposiums, organizations, and presentations to federal policy makers.
